J Hepatology:常喝含糖饮料会引起脂肪肝?!

2015-06-09 佚名 生物谷

来自Tufts大学Jean Mayer USDA人类衰老营养研究中心(USDA HRNCA)的研究人员发现,每天喝含糖饮料的习惯可能会引起非酒精性脂肪肝(NAFLD)。此项研究结果近日在线发表于Journal of Hepatology杂志上。 非酒精性脂肪肝是在肝脏有脂肪的大量堆积,但与饮酒无关。这类脂肪肝可由超声,计算机断层扫描,核磁共振成像及组织活检诊断。在美国,约25%的人患有此类的

来自Tufts大学Jean Mayer USDA人类衰老营养研究中心(USDA HRNCA)的研究人员发现,每天喝含糖饮料的习惯可能会引起非酒精性脂肪肝(NAFLD)。此项研究结果近日在线发表于Journal of Hepatology杂志上。

非酒精性脂肪肝是在肝脏有脂肪的大量堆积,但与饮酒无关。这类脂肪肝可由超声,计算机断层扫描,核磁共振成像及组织活检诊断。在美国,约25%的人患有此类的脂肪肝,但无任何症状。肥胖及超重人群患有非酒精性脂肪肝的风险较高,此类脂肪肝有较高的风险,发展为心脏病及2型糖尿病。含糖饮料是果糖的主要饮食来源,果糖很可能会增高非酒精性脂肪肝的风险。

研究人员们分析了2634份调查问卷,问卷大多来源于中年男性和女性白人。在问卷上的含糖饮料包括含有咖啡因或无咖啡因的可乐,含糖、水果、柠檬水的碳酸饮料,或是非碳酸水果饮料。参与者们接受了计算机断层扫描来测量他们肝脏的脂肪量,研究人员根据已有的非酒精性脂肪肝的标准,来判断参与者是否患有这类脂肪肝。他们发现,问卷中报告自己每日喝多于一瓶含糖饮料的人,比不喝含糖饮料的人,有更高的非酒精脂肪肝发病率。

在研究人员综合考虑了年龄、性别、身体质量指数(BMI),饮食和生活方式等因素后,例如摄入的热量,饮酒和吸烟等因素,他们发现含糖饮料和非酒精性脂肪肝仍相关。然而,考虑了这些因素后,健怡可口可乐与非酒精性脂肪肝无相关关系。

今后,人们需要注意他们饮用含糖饮料的量,或许应该只在特殊的场合才喝这些饮料。 


原始出处:

 Jiantao Ma, Caroline S. Fox, Paul F. Jacques, Elizabeth K. Speliotes, Udo Hoffmann, Caren E. Smith, Edward Saltzman, Nicola M. McKeown.Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts.Journal of Hepatology, June 5, 2015.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=27585, encodeId=bd5d2e585f7, content=少喝饮料, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sun Jun 14 12:50:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426612, encodeId=c48214266127a, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Jun 11 00:29:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26832, encodeId=a436268320f, content=这也能发?, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2332296, createdName=qiaoyingli, createdTime=Wed Jun 10 07:59:00 CST 2015, time=2015-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26662, encodeId=ac5826662b4, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:09:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26552, encodeId=b108265523a, content=以后要小心了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 09 16:01:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
    2015-06-14 huangwukui

    少喝饮料

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=27585, encodeId=bd5d2e585f7, content=少喝饮料, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sun Jun 14 12:50:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426612, encodeId=c48214266127a, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Jun 11 00:29:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26832, encodeId=a436268320f, content=这也能发?, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2332296, createdName=qiaoyingli, createdTime=Wed Jun 10 07:59:00 CST 2015, time=2015-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26662, encodeId=ac5826662b4, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:09:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26552, encodeId=b108265523a, content=以后要小心了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 09 16:01:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
    2015-06-11 gwc384
  3. [GetPortalCommentsPageByObjectIdResponse(id=27585, encodeId=bd5d2e585f7, content=少喝饮料, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sun Jun 14 12:50:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426612, encodeId=c48214266127a, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Jun 11 00:29:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26832, encodeId=a436268320f, content=这也能发?, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2332296, createdName=qiaoyingli, createdTime=Wed Jun 10 07:59:00 CST 2015, time=2015-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26662, encodeId=ac5826662b4, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:09:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26552, encodeId=b108265523a, content=以后要小心了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 09 16:01:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
    2015-06-10 qiaoyingli

    这也能发?

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=27585, encodeId=bd5d2e585f7, content=少喝饮料, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sun Jun 14 12:50:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426612, encodeId=c48214266127a, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Jun 11 00:29:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26832, encodeId=a436268320f, content=这也能发?, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2332296, createdName=qiaoyingli, createdTime=Wed Jun 10 07:59:00 CST 2015, time=2015-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26662, encodeId=ac5826662b4, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:09:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26552, encodeId=b108265523a, content=以后要小心了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 09 16:01:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
    2015-06-09 huaxipanxing

    看看

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=27585, encodeId=bd5d2e585f7, content=少喝饮料, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Sun Jun 14 12:50:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426612, encodeId=c48214266127a, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Jun 11 00:29:00 CST 2015, time=2015-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26832, encodeId=a436268320f, content=这也能发?, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c2332296, createdName=qiaoyingli, createdTime=Wed Jun 10 07:59:00 CST 2015, time=2015-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26662, encodeId=ac5826662b4, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Tue Jun 09 19:09:00 CST 2015, time=2015-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=26552, encodeId=b108265523a, content=以后要小心了, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://api.medsci.cn/resource/upload/20150526/IMG5564536F3C41D5237.jpg, createdBy=4c0c1612254, createdName=summer474cn, createdTime=Tue Jun 09 16:01:00 CST 2015, time=2015-06-09, status=1, ipAttribution=)]
    2015-06-09 summer474cn

    以后要小心了

    0

相关资讯

Hepatology:频繁吃零食可导致脂肪肝

美国儿童消耗的能量中有多达27%来源于高糖高脂零食。糖和脂肪摄入过多被认为可导致肝脏脂肪变性和肥胖,但是,不健康的饮食习惯是否也可以引起肝脏脂肪变性和肥胖尚不清楚。 为此,来自荷兰阿姆斯特丹大学学术医疗中心的Karin E. Koopman教授及其团队进行了一项研究,探讨频繁进餐是否也可引起肝内和腹部脂肪堆积加重。该研究结果发表在2014年08月的Hepatology杂志上。 该研究中,Koo

Oncotarget:PTPRO介导的自噬可以阻止脂肪肝和肝细胞癌发生

以往研究表明细胞自噬在非酒精性脂肪肝(NASH)和肝细胞癌(HCC)的进展中起非常重要的作用。蛋白酪氨酸磷酸酶受体O (PTPRO)是最近发现的肿瘤抑制因子,但是关于它在NASH的研究很少。近来有研究,证明PTPRO介导的细胞自噬与胰岛素抵抗、脂代谢、肝癌发生相关。 研究者选取同源的野生型小鼠(对照组)和ptpro−/−小鼠(试验组)作为实验对象,首先使用二乙基亚硝胺造NAS

Child Obes:规范肥胖儿的筛查和治疗

背景:美国约有30%的儿童受到肥胖和超重问题的困扰。许多儿童有肥胖相关并发症,包括高血压、血脂异常、脂肪肝、糖尿病、多囊卵巢综合征、睡眠障碍、心理问题等等。这些患儿往往需要进行常规筛查和治疗。但是,由于初级医院的儿童医生通常不能很好地解决肥胖并发症的问题,他们常常将这些儿童转诊至儿科专科医生。然而,由于美国儿科专科医生的缺乏,美国大约有1250万的肥胖儿童不能得到很好的救治。本文的主要目的是规范儿

Science:二硝基酚在动物模型中成功逆转2型糖尿病和脂肪肝

耶鲁大学研究人员开发了一种控释口服药物,可以用来治疗2型糖尿病和脂肪肝,在大鼠模型已经获得了成功。研究结果发表于Science杂志上。基于早期的研究结果,耶鲁大学医学院Gerald I. Shulman博士领衔的研究团队试图在动物模型,观察一种70年前用于减重的药物--线粒体质子载体2,4-二硝基酚(DNP)是否能够安全治疗NAFLD/NASH和2型糖尿病。早期研究结果显示,DNP相关的药物毒性与

JBC:FGF21可能缓解内质网应激诱导的脂肪肝中的作用

The Journal of Biological Chemistry发表了中国科学院上海生命科学研究院营养科学研究所刘勇研究组与上海交通大学附属第六人民医院贾伟平研究组的最新合作研究:Fibroblast Growth Factor 21 Is Regulated by the IRE1α-XBP1 Branch of the Unfolded Protein Response an

Scientific Reports:心血来潮的一次运动或许并不能让你更健康

肝脂质含量(肝内脂质,IHL)的增加会导致其代谢并发症风险增加。有研究表明,有规律的耐力训练可以减少代谢疾病风险,可以降低IHL水平。但是短期身体活动是否与耐力训练有类似效果还不知道。